Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept Deferiprone in Pelizaeus-Merzbacher Disease
2021-000070-29Phase 2Active
- Sponsor
- VU University Medical Center
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferiprone in Pelizaeus-Merzbacher disease (PMD), sponsored by VU University Medical Center. Primary endpoint: Gross motor function. Started Jul 2022; status: active.
02
Drugs
deferiprone
03
Conditions
Pelizaeus-Merzbacher disease (PMD)
Beyond the preview
Go deeper on 2021-000070-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000070-29.